CN106474192A - Apply in cinnamomum cassia extract and its preparation and its preventing and treating Alzheimer disease - Google Patents
Apply in cinnamomum cassia extract and its preparation and its preventing and treating Alzheimer disease Download PDFInfo
- Publication number
- CN106474192A CN106474192A CN201611147555.4A CN201611147555A CN106474192A CN 106474192 A CN106474192 A CN 106474192A CN 201611147555 A CN201611147555 A CN 201611147555A CN 106474192 A CN106474192 A CN 106474192A
- Authority
- CN
- China
- Prior art keywords
- preparation
- cassia tree
- chinese cassia
- extract
- cinnamomum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000037364 Cinnamomum aromaticum Species 0.000 title claims abstract description 48
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 title claims abstract description 48
- 235000021511 Cinnamomum cassia Nutrition 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 24
- 241000522254 Cassia Species 0.000 claims abstract description 49
- 239000000706 filtrate Substances 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 8
- 239000008367 deionised water Substances 0.000 claims abstract description 5
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 238000007605 air drying Methods 0.000 claims abstract description 4
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 23
- OOCCDEMITAIZTP-QPJJXVBHSA-N (E)-cinnamyl alcohol Chemical compound OC\C=C\C1=CC=CC=C1 OOCCDEMITAIZTP-QPJJXVBHSA-N 0.000 claims description 20
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 19
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 19
- 235000013985 cinnamic acid Nutrition 0.000 claims description 19
- 229930016911 cinnamic acid Natural products 0.000 claims description 19
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 claims description 11
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 claims description 11
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims description 11
- OOCCDEMITAIZTP-UHFFFAOYSA-N allylic benzylic alcohol Natural products OCC=CC1=CC=CC=C1 OOCCDEMITAIZTP-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 239000000835 fiber Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 5
- 235000013824 polyphenols Nutrition 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 235000013372 meat Nutrition 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000013312 flour Nutrition 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 8
- 239000007864 aqueous solution Substances 0.000 abstract description 6
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 206010039966 Senile dementia Diseases 0.000 abstract description 3
- 238000002386 leaching Methods 0.000 abstract description 3
- 230000000116 mitigating effect Effects 0.000 abstract description 3
- 239000006228 supernatant Substances 0.000 abstract description 3
- 238000005119 centrifugation Methods 0.000 abstract description 2
- 239000012141 concentrate Substances 0.000 abstract description 2
- 238000001914 filtration Methods 0.000 abstract description 2
- 238000010438 heat treatment Methods 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 238000009413 insulation Methods 0.000 abstract 1
- 238000003809 water extraction Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 8
- 239000013558 reference substance Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001073 episodic memory Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 229960004538 alprazolam Drugs 0.000 description 2
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000003930 cognitive ability Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 102000013498 tau Proteins Human genes 0.000 description 2
- 108010026424 tau Proteins Proteins 0.000 description 2
- ZQAQXZBSGZUUNL-BJUDXGSMSA-N 2-[4-(methylamino)phenyl]-1,3-benzothiazol-6-ol Chemical compound C1=CC(N[11CH3])=CC=C1C1=NC2=CC=C(O)C=C2S1 ZQAQXZBSGZUUNL-BJUDXGSMSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 208000006888 Agnosia Diseases 0.000 description 1
- 241001047040 Agnosia Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 244000080208 Canella winterana Species 0.000 description 1
- 235000008499 Canella winterana Nutrition 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000002038 Muscle Hypertonia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241001627955 Tetraodon lineatus Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000002242 deionisation method Methods 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001353 entorhinal cortex Anatomy 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 206010019465 hemiparesis Diseases 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses applying in cinnamomum cassia extract and its preparation and its preventing and treating Alzheimer disease.It is that hot water extraction is carried out to Chinese cassia tree first, obtains cinnamomum cassia extract.The cinnamomum cassia extract leaching process is（1）Chinese cassia tree raw material is crushed by choosing, must crush Chinese cassia tree；（2）Crushing Chinese cassia tree water is accounted for crushing in Chinese cassia tree to add；The water is deionized water, makes the crushing Chinese cassia tree aqueous solution,（3）The heating of the Chinese cassia tree aqueous solution, insulation will be crushed；（4）Centrifugation is separated by filtration, and collects supernatant, is former filtrate；（5）By former filtrate through reduced pressure concentration, filtrate must be concentrated；（6）To concentrate that filtrate is vacuum dried, heated-air drying or be spray-dried to obtain cinnamomum cassia extract.Which is applied on the medicine for the treatment of senile dementia, and its clinical effectiveness is good, and toxic and side effect is little；Which has remarkable result to mitigating ailing, raising patients ' life quality.
Description
Technical field：
The invention belongs to technical field of traditional Chinese medicines, and in particular to a kind of preparation method and applications of cinnamomum cassia extract, particularly meat
Apply in osmanthus extract and its preparation and its preventing and treating Alzheimer disease.
Background technology
Chinese cassia tree（Classification system：Cinnamomum cassia Presl）, it is the dry bark of canella Chinese cassia tree.Bark fragrance,
Spices can be made, be also a kind of rare Chinese medicine.With the effects such as complement sun, warming spleen and stomach, removing internal cold, promoting blood circulation.Gate of vitality's fire can be controlled
Decline, cold weak pulse of limb, yang depletion are collapsed, stomachache is had loose bowels, cold hernia run quickly globefish, waist and knee crymodynia, Amenorrhea abdominal mass, cloudy subcutaneous ulcer, streamer, and empty sun is floating
More, heat in the upper and cold in the lower.Inventor is chancing on Chinese cassia tree and its extract to changing to Chinese cassia tree and its extract when carrying out experimental study
The clinical symptoms of kind the nervous system disease, especially Alzheimer disease have remarkable effect, using Chinese cassia tree especially its extraction
Thing has remarkable result to mitigating ailing, raising patients ' life quality.
Cinnamomum cassia extract can have obvious humidification to immune function of human body；Its mechanism of action is which can strengthen human body T
The propagation and differentiation of lymphocyte and bone-marrow-derived lymphocyte, and strengthen its function；Strengthen the killing ability of killing cell and monokaryon is gulped down
Phagocytal phagocytic function.The result of study is the natural traditional Chinese medicine that screening is effective and has no toxic side effect.But which is to alzheimer '
The application preventing and treating of silent disease aspect there are no document report.
Alzheimer disease（Alzheimer ' s disease, AD）, it is that a kind of memory of progressive is with cerebral damage
The degenerative neural disease of feature, gains the name because German doctor Alzheimer (Alois Alzheimer) is described at first.
The symptom of Alzheimer disease is mainly shown as the different degrees of forfeiture of patient's memory and cognitive ability, and behavioral activity hinders
Hinder.With advancing of disease, patient can gradually lose self care ability, bring to personal family and the society of patient heavy
Burden.Epidemiology survey shows：Europe elderly population age standardization AD illness rate is 4.4% within 2000, and women's illness rate is about
3 times of male sex.Estimate that there is AD patient 6,000,000 in China, it is contemplated that to the year two thousand forty, the whole world will have 81,100,000 old dementia patients.AD
Characteristic pathological become and turn to atrophy of cerebral cortex, and deposit with amyloid-beta, neurofibrillary tangles, mass memory
Property neuron number reduce, and the formation of senile plaque expelling.The typical clinical manifestations of Alzheimer disease are:1. memory disorders：Learn
Practise new knowledge or information, recall the capability defect of conventional knowledge or information.2. cognitive ability declines：Aphasia, appraxia
Disease, agnosia, the senior integration function obstacle of brain, such as plan, tissue, successively sequence and abstract thinking ability obstacle etc..3. sick
Cheng Tedian is slow onset, and progressive decrease of cognitive function causes significantly social or professional dysfunction, compared with the past
Assume functional level to be decreased obviously.4. hypermyotonia in physiological function, human body flexing, the course of disease be in progressive, typically experience 8～
10 years or so, advanced dementia is finally developed into, Chang Yin is with the secondary body disease such as pressure ulcer, fracture, pneumonia, malnutrition
Disease or exhaustion and cause death.
Alzheimer disease was often produced after 50 years old, is started slower development, is difficult to be found.PD is roughly divided into
Three phases：（1）Forgetful phase, performance are to remember, orient, perceiving, language, calculating, thinking analysis, judging and complete complex steps
Etc. going down for ability, in personal preference, reading, the time minimizing of cost, fatiguability, dizziness, palpitaition, food in social activities is participated in
Be intended to go down, interest and initiative decline, emotional lability, indifferent or depressed etc..But work familiar to can also even keeping over
Or technical ability, independent viability is kept, is often mistakenly thought of as neurosis or normally aging and ignore treatment.（2）The chaotic phase:This
Individual period, above-mentioned symptom substantially increase, and prominent performance is that visual space identification obstacle substantially increases, it is easy to lost；Wear the clothes change
Highly difficult, or even trousers pledged clothes wear；Do not recognize the looks of friend or relatives, forget their name yet；Can not be with
Others talks.Even there is behavior and the change of personality, such as originally meticulous, careful careful people goes to seed, lacks
Weary humiliation and moral sense, movement that is selfish and often doing a little abnormalities.Centered on self, it is indifferent to people and the thing of surrounding, does not note
Health.Usually depressive anxiety, delusion of jealousy, unsociable and eccentric, exciting irritability etc..（3）Extreme dementia phase:The most of work(of patient body
Can lose, can't take care of oneself, such as have a meal, wear the clothes, having a bath is both needed to people's treatment, the just urinary incontinence.Patients with terminal is liied in bed completely, life
Entirely by others look after, the course of disease maintain 5～10 years or so and dead.
Treatment to Alzheimer disease there is no the medicine of specific treatment or reverse disease progression at present.Clinical at present
Upper conventional therapeutic strategy has：（1）Increase intracerebral acetylcholine（Ach）The medicine of concentration；（2）Promote intracerebral cholinergic neuron
Survival or improve the medicine of its Nerve conduction；（3）The generation for reducing Α β or the medicine for promoting its degraded.Global at present
Medical personal can effectively prevent and treat medicine or the method for AD in actively searching.Clinical conventional vasodilator, brain metabolic activation
The medicines such as agent, glutamate receptor adjusting control agent, clinical effectiveness be not good, and toxic and side effect is larger；Therefore, the medicine of senile dementia is treated
On improvement be current urgent need to resolve problem.
Content of the invention：
Apply in cinnamomum cassia extract of the present invention and its preparation and its preventing and treating Alzheimer disease.It is that hot water leaching is carried out to Chinese cassia tree first
Carry, obtain cinnamomum cassia extract.Which is applied on the medicine for the treatment of senile dementia, and its clinical effectiveness is good, and toxic and side effect is little；
Which has remarkable result to mitigating ailing, raising patients ' life quality.
A kind of cinnamomum cassia extract of the present invention, constitutes Chinese cassia tree polyphenol 30-60Wt% including following mass component, and cinnaman contains
Amount 20-40 Wt%, and cinnamic acid 0.1-5Wt%, cinnamic acid 0.01-1Wt%, cinnamyl alcohol 0.01-1Wt%, cumarin 0.01-
1Wt%, balance of Chinese cassia tree fiber.
Also include coumaric acid 0.01-0.5Wt% in cinnamomum cassia extract of the present invention.
It is another object of the present invention to a kind of preparation method of cinnamomum cassia extract, with Chinese cassia tree as raw material, including following method,
After Chinese cassia tree is crushed, add water and be uniformly mixed, then heating extraction 1-5 hour, filter, filtrate is obtained, concentrating filter liquor is done
Dry cinnamomum cassia extract.
A kind of preparation method of cinnamomum cassia extract, is preferably added water as deionized water, control addition deionized water
Amount be 8-20 times of Chinese cassia tree quality, control heating-up temperature is 40-90 DEG C.
A kind of preparation method of cinnamomum cassia extract, preferably described concentration is reduced pressure concentration, and filtrate is concentrated by control
To the 1/8-1/12 of former filtrate weight, the drying is vacuum drying, heated-air drying or spray drying..
Described crush Chinese cassia tree is that Chinese cassia tree is crushed to 20-100 mesh, must crush Chinese cassia tree.
Yet another object of the present invention is a kind of cinnamomum cassia extract and its preparation answering in treatment Alzheimer disease preventing and treating
With.
It is preferred that the application of described cinnamomum cassia extract and its preparation in treatment Alzheimer disease preventing and treating, its described preparation
For preparation in pharmacy, in the pharmacy preparation be tablet, capsule, powder, pill any one.
Cinnamomum cassia extract of the present invention includes following mass component composition Chinese cassia tree polyphenol 30-60Wt%, and cinnaman contains
Amount 20-40 Wt%, and cinnamic acid 0.1-5Wt%, cinnamic acid 0.01-1Wt%, cinnamyl alcohol 0.01-1Wt%, cumarin 0.01-
1Wt%, balance of Chinese cassia tree fiber.
Also include coumaric acid 0.01-0.5Wt% in cinnamomum cassia extract of the present invention.
Which effectively can be prevented and treated to Alzheimer disease, and toxic and side effect is little, and clinical effectiveness is notable, while can mitigate
Ailing, raising patients ' life quality has remarkable result.
The cinnamomum cassia extract of the present invention is that leaching process is with Chinese cassia tree as raw material（1）Chinese cassia tree raw material is crushed to 20- by choosing
100 mesh, must crush Chinese cassia tree；（2）Account for, to crushing to add in Chinese cassia tree, the water for crushing 8-20 times of weight of Chinese cassia tree；The water is deionization
Water, makes the crushing Chinese cassia tree aqueous solution,（3）The Chinese cassia tree aqueous solution will be crushed 40-90 DEG C is heated to, be incubated 1-5 hour；（4）Centrifugation or
It is separated by filtration, supernatant is collected, is former filtrate；（5）By former filtrate through being evaporated to the 1/8-1/12 of former filtrate weight, obtain dense
Contracting filtrate；（6）To concentrate that filtrate is vacuum dried, heated-air drying or be spray-dried to obtain cinnamomum cassia extract.
Cinnamomum cassia extract of the present invention, constitutes Chinese cassia tree polyphenol 30-60Wt% including following mass component, and cinnaman contains
Amount 20-40 Wt%, and cinnamic acid 0.1-5Wt%, cinnamic acid 0.01-1Wt%, cinnamyl alcohol 0.01-1Wt%, cumarin 0.01-
1Wt%, balance of Chinese cassia tree fiber.
Above-mentioned cinnamomum cassia extract and its preparation are can be applicable in treatment Alzheimer disease preventing and treating, and preparation of the present invention is
The formulations such as tablet in pharmacy, capsule, powder, pill made by preparation in pharmacy, its through proper method.
Below with the inventive method prepare cinnamomum cassia extract Alzheimer disease preventing and treating in application carry out in detail
Illustrate, the Chinese cassia tree is extracted includes following mass component composition Chinese cassia tree polyphenol 30-60Wt%, cinnaman content 20-40
Wt%, and cinnamic acid 0.1-5Wt%, cinnamic acid 0.01-1Wt%, cinnamyl alcohol 0.01-1Wt%, cumarin 0.01-1Wt%, balance of
Chinese cassia tree fiber.
Also include coumaric acid 0.01-0.5Wt% in cinnamomum cassia extract of the present invention.
Be presented herein below utilize cinnamomum cassia extract of the present invention or with Chinese herb medicine prevention together for Alzheimer disease and control
Treat applicable cases to be described as follows.
Clinical efficacy is summarized：
General data：A kind of cinnamomum cassia extract is applied to clinical observation case 36,58～82 years old age, average age
74 years old, wherein male 25, female 11.The course of disease -5 years 6 months.Control group clinical observation case 27,61～81 years old age,
Average age 75 years old, wherein man 17, female 10.The course of disease -6 years 12 months.
Diagnostic criteria:According to US National neuropathy aphasis palsy research institute AD and relevant disease association
（NINCDS-ADRDA）The diagnostic criteria of regulation.May be the diagnostic criteria of AD:A plus one or more supportive features B,
C, D or E.
Kernel diagnosis standard：
A. there is early stage and significant episodic memory obstacle, including following characteristics
1. patient or insider tell the slow progressive hypomnesia for having more than 6 months.
2. test finds the objective evidence of the episodic memory infringement for having serious:Predominantly recall impaired, by hint or again
Recognize test to significantly improve or recover normal.
3., when AD falls ill or AD is in progress, episodic memory infringement can be independent to other Cognitive function changes or related.
Supportive feature:
B. gyrus temporalis meduus atrophy
Qualitative evaluation is carried out using visual score（Age norm with reference to specific crowd）, or determined volume is carried out to region of interest
Determine（Age norm with reference to specific crowd）, magnetic resonance display hippocampus, entorhinal cortex, amygdaloid nucleus volume-diminished.
C. abnormal cerebrospinal fluid biomarker；
Amyloid beta 1-42（Aβ1-42）Concentration reduces, and total Tau protein concentration is raised, or phosphorylated Tau protein concentration liter
Height, or the combination of this three；
The biomarker of simultaneously empirical tests is found in the future.
The specificity imaging of D.PET neuroimaging,
Bilateral temporo, top glucose metabolic rate lower；
The part of other empirical tests, including Pittsburgh compound B or 1- 6- [（2-18F- fluoro ethyl）- methylamino] -2- naphthyl } -
The third dicyan of ethylidene（18F-FDDNP）.
E. the autosomal dominant mutation for having clear and definite AD related in lineal relative.
Exclusion standard：
Medical history：Sudden onset；There are following symptoms in early stage：Gait disorder, epileptic attack, behavior change；
Clinical manifestation：Focal neurological manifestations, including hemiparesis, anaesthesia, defect of visual field；Early stage EPS；
Other internal diseases, serious remember and related symptoms to being enough to cause：Non-ad dementias, major depression, cerebrovascular disease, poisoning
And metabolic disorder, these also need to special examined.The FLAIR of gyrus temporalis meduus MRI consistent with infectious or vascular injury or
T2 abnormal signal.
Make a definite diagnosis the standard of AD：
If there are following performance, you can make a definite diagnosis AD：Existing clinic and in a organized way pathology（Biopsy of brain or postmortem）Evidence, with NIA-
It is consistent that standard is made a definite diagnosis in the AD postmortem that Reagan is required.Both sides standard must simultaneously meet.
Existing clinic has science of heredity again（The mutation of No. 1, No. 14 or No. 21 chromosome）AD diagnostic evidence；Both sides mark
Standard must simultaneously meet.
Usage and dosage：During clinical practice, per agent 0.6g containing cinnamomum cassia extract, one day is one, and 30 doses is a course for the treatment of, early,
Evening twice before meals half an hour warm water take.Control group takes alprazolam, starts with low dose of a, 0.2mg（Half）, one day
3 times, maximal tolerance dose is gradually increased to, maximum limits the quantity one up to 4mg（10）.
Criterion of therapeutical effect：Cure：Clinical symptoms are wholly absent；Effective：Clinical symptoms improve；Invalid：Clinical symptoms
Unchanged or increase.
Therapeutic effect：In clinical observation case, the 1-3 course for the treatment of of taking medicine, cure 5, effective 27, invalid 4；
Control group cures 3, effective 22, invalid 2.
This experimental result shows that cinnamomum cassia extract is better than alprazolam for the therapeutic effect of Alzheimer disease.
Description of the drawings：
Fig. 1, is the HPLC spectrogram of cinnamomum cassia extract prepared by the present invention；
Fig. 2, is the HPLC spectrogram of this coumaric acid, cumarin, cinnamyl alcohol, cinnamic acid and cinnamic acid mixing reference substance.
Explanation：The preparation of reference substance solution, is that precision weighs coumaric acid, cumarin, cinnamyl alcohol, cinnamic acid and cassia bark respectively
5.12 mg of sour reference substance, 7.31 mg, 14.27 mg, 12.50 mg, 4.44 mg, are respectively placed in 25 mL measuring bottles, plus methyl alcohol
Dissolve and scale is diluted to, shake up, make containing 0.2048 mg mL of coumaric acid-1, 0.2924 mg mL of cumarin-1, Chinese cassia tree
0.5708 mg mL of alcohol-1, 0.5000 mg mL of cinnamic acid-1With 0.1776 mg mL of cinnamic acid-1Reference substance deposit molten
Liquid, standby.Accurate coumaric acid, cumarin, cinnamyl alcohol, cinnamic acid and each 1mL of cinnamic acid reference substance stock solution of drawing is placed in 10
In mL volumetric flask, scale is diluted to mobile phase, obtain final product containing 0.02048 mg mL of coumaric acid-1, cumarin 0.02924
mg·mL-1, 0.05708 mg mL of cinnamyl alcohol-1, 0.05000 mg mL of cinnamic acid-1With 0.01776 mg mL of cinnamic acid-1
Reference substance mixed solution.
Sample solution：
The cinnamomum cassia extract for taking the present invention dries 4 h in vacuum drying chamber at 80 DEG C, precision weighs about 5 mg, is placed in 10 mL
Volumetric flask, with constant volume after flowing phased soln.All samples solution all with 0.45 m membrane filtration, enter for liquid chromatogram by filtrate
Sample is analyzed.
Chromatographic condition：
Chromatographic column is Kromasil C18 post（4.6 mm × 250 mm, 5 μm）；Mobile phase is methyl alcohol: water: phosphoric acid（45∶55∶
0.1, v/v/v）；0.8 mL min of flow velocity-1；280 nm of Detection wavelength；Column temperature is 30 DEG C.With coumaric acid, cumarin, cinnamyl alcohol,
Cinnamic acid and cinnamic acid meter, theoretical cam curve are all higher than 6000.The mixing of coumaric acid, cumarin, cinnamyl alcohol, cinnamic acid and cinnamic acid
Reference substance solution and cinnamomum cassia extract chromatogram.
Specific embodiment：
Embodiment 1：Take after Chinese cassia tree 100kg is crushed to 20-100 mesh, Chinese cassia tree must be crushed；Add softening water-soluble to crushing in Chinese cassia tree
Liquid 800kg is mixed thoroughly, makes the crushing Chinese cassia tree aqueous solution, the crushing Chinese cassia tree aqueous solution that makes is heated to 50 DEG C and is extracted 3 hours, and protect
Temperature 2 hours, filters, and collects supernatant, is former filtrate, and by former filtrate reduced in volume to 100kg, vacuum drying obtains Chinese cassia tree extraction
Thing.The preparation cinnamomum cassia extract of above-mentioned preparation being prepared into by medical procedures in pharmacy.Such as take cinnamomum cassia extract and add starch
With microcrystalline cellulose granulation, compressing tablet, per piece 0.2g containing cinnamomum cassia extract, especially 1-2 stage Alzheimer sufferer of each stage
Person daily 3,30 days is a course for the treatment of.This product also can be taken by normal aging people as health products, for preventing A Erci
The silent disease in sea develops.
Claims (8)
1. a kind of cinnamomum cassia extract, constitutes Chinese cassia tree polyphenol 30-60Wt%, cinnaman content 20-40 including following mass component
Wt%, and cinnamic acid 0.1-5Wt%, cinnamic acid 0.01-1Wt%, cinnamyl alcohol 0.01-1Wt%, cumarin 0.01-1Wt%, balance of
Chinese cassia tree fiber.
2. a kind of cinnamomum cassia extract according to claim 1, also includes coumaric acid in cinnamomum cassia extract described in its feature
0.01-0.5Wt%.
3. a kind of preparation method of cinnamomum cassia extract, with Chinese cassia tree as raw material, including following method, after Chinese cassia tree is crushed, adds water and stirs
Mix and mix, extraction 1-5 hour is then heated and be incubated, is filtered, former filtrate is obtained, by former concentrating filter liquor, dry Chinese cassia tree
Extract.
4. a kind of preparation method of cinnamomum cassia extract according to claim 3, it is characterized in that described add water as deionized water, control
It is 8-20 times of Chinese cassia tree quality that system adds the amount of deionized water, controls heating-up temperature for 40-90 DEG C.
5. a kind of preparation method of cinnamomum cassia extract according to claim 3, is characterized in that described concentration is reduced pressure concentration, control
Former filtrate is concentrated into system the 1/8-1/12 of former filtrate weight, and the drying is vacuum drying, heated-air drying or spray drying.
6. a kind of preparation method of cinnamomum cassia extract according to claim 3, it is characterized in that described Chinese cassia tree is crushed be by meat
Cassia lignea flour is broken to 20-100 mesh.
7. the application of a kind of cinnamomum cassia extract and its preparation in treatment Alzheimer disease preventing and treating.
8. the application of cinnamomum cassia extract according to claim 7 and its preparation in treatment Alzheimer disease preventing and treating, its
Be characterized in that described be made as preparation in pharmacy, in the pharmacy preparation be tablet, capsule, powder, pill any one.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611147555.4A CN106474192A (en) | 2016-12-13 | 2016-12-13 | Apply in cinnamomum cassia extract and its preparation and its preventing and treating Alzheimer disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611147555.4A CN106474192A (en) | 2016-12-13 | 2016-12-13 | Apply in cinnamomum cassia extract and its preparation and its preventing and treating Alzheimer disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106474192A true CN106474192A (en) | 2017-03-08 |
Family
ID=58285314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611147555.4A Pending CN106474192A (en) | 2016-12-13 | 2016-12-13 | Apply in cinnamomum cassia extract and its preparation and its preventing and treating Alzheimer disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106474192A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114470038A (en) * | 2022-03-28 | 2022-05-13 | 北京诺迪博尔医药科技有限公司 | Composition for treating Alzheimer disease-senile cognitive disorder |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110029714A (en) * | 2009-09-16 | 2011-03-23 | 한국 한의학 연구원 | Composition for prevention and treatment of dementia |
-
2016
- 2016-12-13 CN CN201611147555.4A patent/CN106474192A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110029714A (en) * | 2009-09-16 | 2011-03-23 | 한국 한의학 연구원 | Composition for prevention and treatment of dementia |
Non-Patent Citations (1)
| Title |
|---|
| DYLAN W. PETERSON ET AL: "Cinnamon Extract Inhibits Tau Aggregation Associated with Alzheimer’s Disease In Vitro", 《JOURNAL OF ALZHEIMER’S DISEASE》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114470038A (en) * | 2022-03-28 | 2022-05-13 | 北京诺迪博尔医药科技有限公司 | Composition for treating Alzheimer disease-senile cognitive disorder |
| CN114470038B (en) * | 2022-03-28 | 2023-10-24 | 北京诺迪博尔医药科技有限公司 | Composition for treating Alzheimer's disease-senile cognitive dysfunction |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506451A (en) | Walnut oligopeptide powder and its preparation method and use | |
| CN103393736B (en) | A kind of for pharmaceutical composition treating Alzheimer and its production and use | |
| JP5856725B2 (en) | Pharmaceutical composition for treating or preventing depression | |
| CN103536757B (en) | Traditional Chinese medicine composition having effects of tonifying kidney, replenishing essence, tonifying qi, nourishing blood and consolidating basis, and preparation method and application thereof | |
| US11253566B2 (en) | Composition for ameliorating, or treating depression and anxiety disorder comprising Fraxinus rhynchophylla extract as effective ingredient | |
| CN106474192A (en) | Apply in cinnamomum cassia extract and its preparation and its preventing and treating Alzheimer disease | |
| JP2008050331A (en) | New dietary composition useful for dementia | |
| CN104721732B (en) | A kind of herbal composite for treating senile dementia | |
| CN103735761B (en) | A kind of pharmaceutical composition preventing and treating Alzheimer disease and preparation method thereof | |
| CN1205944C (en) | Composition of Chinese medicine | |
| TWI517853B (en) | A composition for treating a vascular injury or a disease-related disease | |
| CN104095938A (en) | Mongolian medicine preparation for treating depression | |
| CN113116934A (en) | Application of maggot for treating senile dementia | |
| KR100697316B1 (en) | Extract for Improving the Symptoms of Dementia and Composition Containing the Same | |
| CN108379379A (en) | Chinese medicine composition for acute stage of gout | |
| CN109464451A (en) | It is a kind of to treat neurasthenic drug and preparation method thereof | |
| CN109847044B (en) | Application of Sishen water extract in preparation of drug for resisting Parkinson's disease | |
| CN104288670B (en) | One kind treatment or/and prevention Alzheimer disease drugs composition and its production and use | |
| CN117797219A (en) | Traditional Chinese medicine composition for preventing and treating Alzheimer disease cognitive dysfunction, preparation method and application thereof | |
| CN106474191A (en) | Cinnamomum cassia extract and preparation method and its application in treatment of Parkinson disease | |
| CN100571722C (en) | Treatment is suffered from a deficiency of the kidney and the pharmaceutical composition of climacteric syndrome and preparation method thereof | |
| CN113842406A (en) | Application of mulberry aqueous extract in preparation of medicine for treating Alzheimer's disease | |
| CN102138982B (en) | Compound valeriana amurensis composition for treating senile dementia, and preparation method and application thereof | |
| CN107029164A (en) | A kind of pure Chinese medicine composition and pure Chinese medicinal preparation prepared therefrom for treating cognitive function attenuating | |
| CN109549972B (en) | Application of traditional Chinese medicine composition in preparation of anti-Parkinson's disease medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170308 |
|
| RJ01 | Rejection of invention patent application after publication |